Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14994067 | 1.00 | RIPK1 (0.33) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL16246924 | 1.00 | RIPK1 (0.33) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL791000 | 1.00 | RIPK1 (0.33) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL344649 | 1.00 | RIPK1 (0.33) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL771956 | 0.90 | POLB (0.41) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL5469615 | 0.90 | POLB (0.41) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL506328 | 0.90 | RIPK1 (0.31) | RIPK1POLBL3MBTL1 | |
| SCHEMBL1975621 | 0.90 | POLB (0.41) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL8646401 | 0.90 | POLB (0.41) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL6398284 | 0.86 | RIPK1 (0.31) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849019-A | A kind of azepine Cydic amide derivatives and preparation method thereof and purposes in medicine | 四川海思科制药有限公司 | 2018-03-27 | — | — | CN | disclosed |
| WO-2017125060-A1 | NITROGENOUS HETEROCYCLIC AMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATION | 四川海思科制药有限公司 | 2017-07-27 | — | — | WO | disclosed |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-8604049-B2 | 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| EP-2432555-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110263549-A1 | 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263549-A1 | 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS | NR4A3, NR4A1, NR1I3 | RIPK1 4481/4885POLB 4291/4885L3MBTL1 4567/4885 |
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | RIPK1 3797/4885POLB 2575/4885L3MBTL1 1179/4885 |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | HTR4, HTR3B, HTR3A | RIPK1 1816/4885POLB 2810/4885L3MBTL1 4880/4885 |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | RIPK1 2296/4885POLB 2914/4885L3MBTL1 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.